Registry for High-Risk Pancreatic Cancer
This observational study is creating a registry for people at high risk for pancreatic cancer (PDAC). The goal is to find and confirm new ways to detect pancreatic cancer early. Researchers will collect blood and pancreatic juice samples, and radiology images like MRIs, over up to 10 years. This information will help develop advanced computer programs (machine learning) to identify early signs of cancer and people at high risk. You can join if you are 18 or older, can give consent, and meet specific high-risk criteria. You cannot join if you have already had pancreatic cancer or a total pancreatectomy. The study status is currently unclear, but it plans to enroll 5000 participants.
- Study design
- This is an observational study, meaning researchers will collect information without giving new treatments. It aims to enroll 5000 participants.
- What's involved
- You would provide blood samples at enrollment and before any pancreatic surgery, and pancreatic juice samples if you have certain endoscopy procedures. Some participants might also receive research MRIs at baseline and every 3 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will collect samples and images for up to 10 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
At a glance
Conditions
NCT06151223
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Mayo Clinic in Rochester
Rochester, Minnesotastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Shounak Majumder, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Collection of biospecimen samples (blood and pancreatic juice)Up to 10 years
Sufficient biospecimens (blood and pancreatic juice) will be collected in 10 years from participants to provide a resource for nested case-control studies of promising biomarkers for discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC)..
- Collection of radiology images and videosUp to 10 years
Collect and archive radiology images and videos obtained during esophagogastroduodenoscopy (EDG)-endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP) in high risk individuals undergoing screening and surveillance tests. An imaging dataset designed for studies of promising imaging biomarkers and developing AI-assisted algorithms can be collected within10 years.